In conclusion, this study found that GS-Rd regulates APP transcription through the MAPK pathway to reduce Aβ mRNA levels, thereby reducing the production of Aβ and ROS in AD and providing a new target for the treatment of AD. The gene discussed is GSR; the disease is Alzheimer disease.